Compare CNXN & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | IVA |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | France |
| Employees | N/A | 84 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 1997 | N/A |
| Metric | CNXN | IVA |
|---|---|---|
| Price | $60.49 | $6.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.20 |
| AVG Volume (30 Days) | 64.5K | ★ 381.5K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $18.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.97 | $2.70 |
| 52 Week High | $71.17 | $7.98 |
| Indicator | CNXN | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 57.06 |
| Support Level | $58.57 | $5.79 |
| Resistance Level | $62.42 | $7.17 |
| Average True Range (ATR) | 1.55 | 0.31 |
| MACD | -0.24 | -0.04 |
| Stochastic Oscillator | 40.40 | 54.43 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.